Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 335 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Capricor Therapeutics Inc | CAPR | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.15 | 2.81% | 5.48 | 07:00:01 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 5.33 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 7 | 335 | - | 2.68 - 8.2212 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 07:00:03 | 2 | US$ 5.48 | USD |
Capricor Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 167.36M | 31.40M | - | 25.18M | -22.29M | -0.71 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Capricor Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CAPR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.90 | 5.682 | 4.70 | 5.15 | 573,594 | 0.58 | 11.84% |
| 1 Month | 7.00 | 7.07 | 4.685 | 5.57 | 382,612 | -1.52 | -21.71% |
| 3 Months | 3.85 | 7.28 | 3.56 | 5.62 | 335,510 | 1.63 | 42.34% |
| 6 Months | 2.70 | 7.28 | 2.68 | 4.88 | 282,141 | 2.78 | 102.96% |
| 1 Year | 3.91 | 8.2212 | 2.68 | 4.76 | 223,082 | 1.57 | 40.15% |
| 3 Years | 4.34 | 8.2212 | 2.56 | 4.58 | 257,639 | 1.14 | 26.27% |
| 5 Years | 0.48 | 12.32 | 0.2526 | 5.88 | 763,102 | 5.00 | 1,041.67% |
Capricor Therapeutics Description
| Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. |
